Prognostic Impact of Surgical Intervention After Lenvatinib Treatment for Advanced Hepatocellular Carcinoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Prognostic Impact of Surgical Intervention After Lenvatinib Treatment for Advanced Hepatocellular Carcinoma

Published:2021-04-26 Issue:12 Volume:28 Page:7663-7672
ISSN:1068-9265
Container-title:Annals of Surgical Oncology
language:en
Short-container-title:Ann Surg Oncol

Author:

Shindoh Junichi,Kawamura Yusuke,Kobayashi Yuta,Kobayashi Masahiro,Akuta Norio,Okubo Satoshi,Suzuki Yoshiyuki,Hashimoto Masaji

Funder

Okinaka Memorial Institute for Medical Research

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Surgery

Link

https://link.springer.com/content/pdf/10.1245/s10434-021-09974-0.pdf

Reference36 articles.

1. Kokudo N, Takemura N, Hasegawa K, et al. Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 (4th JSH-HCC guidelines) 2019 update. Hepatol Res. 2019;49:1109–13.

2. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362:1907–17.

3. Shindoh J, Kaseb A, Vauthey JN. Surgical strategy for liver cancers in the era of effective chemotherapy. Liver Cancer. 2013;2:47–54.

4. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–90.

5. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25–34.

Cited by 74 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Outcome of hepatectomy after systemic therapy for hepatocellular carcinoma: a Japanese multicenter study;Surgery Today;2024-08-27

2. Systemic conversion therapies for initially unresectable hepatocellular carcinoma: a systematic review and meta-analysis;BMC Cancer;2024-08-14

3. Cabozantinib inhibits the growth of lenvatinib-resistant hepatoma cells restoring FTCD expression;Biochemical Pharmacology;2024-08

4. Liver Resection and Transplantation in the Era of Checkpoint Inhibitors;JHEP Reports;2024-08

5. The Treatment of Hepatocellular Carcinoma with Major Vascular Invasion;Cancers;2024-07-14

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3